Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

NCT03324243 is registered in ClinicalTrials.gov with Arog Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03324243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03324243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia
Lead sponsor
Arog Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2018
Completion date
December 31, 2020
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory flt3-mutated aml